Clinical trials: Adjuvant Drug Therapy
Luminal B
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
Neo-CheckRay is a multicenter, open-label phase II study that randomizes luminal B breast cancer subjects candidate for neo-adjuvant chemotherapy in a 1:1:1 ratio in 3 arms: 1.
- Trial name
- Neo-CheckRay (NCT03875573)
- Testing
- Durvalumab, Stereotactic Body Radiotherapy, Oleclumab
- Where
- 7 sites in Belgium, France
- Volunteers
- 147 people
- Sponsor
- Jules Bordet Institute
Prostate Cancer
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00016913
- Testing
- carboplatin, estramustine, paclitaxel
- Where
- 23 sites in United States
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colon Cancer Patients Receiving Chemotherapy in the Adjuvant or Metastatic Setting, Aged 70 or Older
MOST: Mediterranean Oncology Senior Tests
MOST is a longitudinal study whose aim is to test the hypothesis that frailty markers are better at detecting vulnerable patients and that they are a better "Adverse Events" predictive tool than the CGA (Comprehensive Geriatric…
- Trial name
- MOST (NCT02148731)
- Testing
- Frailty markers
- Where
- 8 sites in France
- Volunteers
- 180 people
- Sponsor
- Association Sud pour la Recherche en Oncogériatrie
Breast Cancer
Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer
This is a prospective, non-randomized study which aims to evaluate the response to a neoadjuvant chemotherapy according to the the antitumor immune response in localized breast cancer. 40 patients will be enrolled in the study.
- Trial name
- BREAST IMMUN (NCT01440413)
- Testing
- Blood and tumor sample
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Leon Berard
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant…
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
- Trial name
- PREOPANC-3 (NCT04927780)
- Testing
- Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride
- Where
- 21 sites in Netherlands, Sweden
- Volunteers
- 378 people
- Sponsor
- Erasmus Medical Center
Endometrial Cancer
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
RAINBO MMRd-GREEN is an international, multicenter, phase III randomised trial wherein adjuvant pelvic external beam radiotherapy combined with and followed by durvalumab for one year is compared to adjuvant pelvic external beam…
- Trial name
- RAINBO-GREEN (NCT05255653)
- Testing
- Pelvic external beam radiotherapy, Chemotherapy, Durvalumab
- Where
- 60 sites in Belgium, Canada and 5 more
- Volunteers
- 316 people
- Sponsor
- Leiden University Medical Center
Cholangiocarcinoma
Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients
This is a single-center, prospective, observational and exploratory clinical study. The object of this study is to evaluate the consistency and accuracy of patient-derived organoid model of cholangiocarcinoma to predict the…
- Trial name
- NCT05634694
- Testing
- No interventions.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Colorectal Cancer
Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy
Surgical resection is curative for 75% of stage II and 50% of stage III colon cancer patients. The magnitude of benefit of adjuvant chemotherapy in terms of disease-free (DFS) and overall survival (OS) varies according to TNM…
- Trial name
- ERASE-TMZ (NCT05031975)
- Testing
- Irinotecan, Temozolomide
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Colorectal Cancer
Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- IDEA (NCT00958737)
- Testing
- FOLFOX regimen, CAPOX
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Invasive Breast Carcinoma
Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer
This trial studies the barriers associated with timely chemotherapy given after surgery (adjuvant) in patients with invasive breast cancer.
- Trial name
- NCT04087057
- Testing
- Interview, Medical Chart Review, Questionnaire
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Oesophageal Adenocarcinoma, Chemotherapy Effect
Prehabilitation of Patients With oEsophageal Malignancy Undergoing Peri-operative Treatment
'Pre-EMPT' - A cohort-controlled, interventional study to assess the effects of a pre-emptive exercise programme, or 'prehabilitation', in patients undergoing peri-operative chemotherapy for adenocarcinoma of the lower oesophagus…
- Conditions
- Oesophageal Adenocarcinoma, Chemotherapy Effect, Surgery
- Trial name
- Pre-EMPT (NCT03626610)
- Testing
- Exercise prehabilitation during chemotherapy before surgery
- Where
- United Kingdom
- Volunteers
- 66 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Cervical Cancer
Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in Cervical Cancer
Purpose Primary endpoint To evaluate the 3-year disease free survival Second endpoints To evaluate the 3-year \& 5-year overall survival To analyze the toxicity and the quality of life
- Trial name
- NCT01487226
- Testing
- paclitaxel, Cisplatin 50mg/m2
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- Korean Gynecologic Oncology Group
Advanced Breast Cancer
A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer
The combination of vinflunine and gemcitabine in advanced breast cancer in comparison to paclitaxel and gemcitabine is based on the following points: the significant antitumour activity of vinflunine in metastatic breast cancer…
- Trial name
- VICTORIA (NCT02054338)
- Testing
- Vinflunine+Gemcitabine, Paclitaxel+Gemcitabine
- Volunteers
- 1,004 people
- Sponsor
- Pierre Fabre Medicament
Fatigue After Adjuvant Breast Cancer Treatment
An Intervention to Decrease Fatigue Among Breast Cancer Survivors
This research project is being done to design and then test whether a 10 week program can help reduce the symptoms of being tired and fatigued among women who have had breast cancer.
- Trial name
- NCT00273208
- Testing
- 10 week behavioral intervention program
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mercy Medical Center
Pancreatic Ductal Adenocarcinoma
Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer
A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the pancreatic cancer patients treated with adjuvant chemotherapy.
- Trial name
- AKT (NCT02929797)
- Testing
- CD8+NKG2D+ AKT Cell, Gemcitabine
- Where
- 2 sites in China
- Volunteers
- 72 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Triple-negative Breast Cancer
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
Triple-negative breast cancer (TNBC) is a group of tumors that occurs mainly in young, premenopausal women and accounts for 10-20% of breast cancers.
- Trial name
- ETNA (NCT06078384)
- Testing
- Pembrolizumab 25 mg/ml, Paclitaxel injection
- Where
- 44 sites in France, Spain
- Volunteers
- 354 people
- Sponsor
- UNICANCER
Cancer Colorectal
ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation
In this study, the investigators aimed to apply their previously developed multi-locus blood-based assay targeting circulating tumor DNA methylation to monitor postoperative relapse and evaluate adjuvant chemotherapy efficacy in…
- Trial name
- NCT05536089
- Testing
- a multi-locus blood-based assay
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Singlera Genomics Inc.
Breast Cancer
Usefulness of Ki67 Index in Hormone Receptor-positive Breast Cancer
Gene expression studies have identified at least four molecularly distinct subtypes of breast cancer including two biologically distinct ER-positive subtypes of breast cancer: luminal A and luminal B (with luminal B tumors having…
- Trial name
- NCT01273415
- Where
- South Korea
- Volunteers
- 1,070 people
- Sponsor
- Samsung Medical Center
Gastric Cancer, Adjuvant Chemotherapy, XO
Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH
multicenter, open label, randomaized, phase III The role of post surgery adjuvant chemotherapy is becoming more and more important in AGC (advance gastric cancer).
- Trial name
- NCT01935778
- Testing
- Docetaxel and capecitabine and oxaliplatin, capecitabine and oxaliplatin
- Where
- South Korea
- Volunteers
- 286 people
- Sponsor
- Asan Medical Center
Rectal Carcinoma
Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)
Phase II study of up-front chemotherapy and neo-adjuvant shortcourse radiotherapy for resectable rectal carcinoma. Study Design: Phase II, open-label, single-arm, multi-centre study.
- Trial name
- COLORE (NCT02000050)
- Testing
- FOLFOX4, Tomotherapy, TME (Total Mesorectal Excision)
- Where
- 2 sites in Italy
- Volunteers
- 52 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.